R. Gregory Bociek, MD

home / authors / r-gregory-bociek-md

Articles

R. Gregory Bociek, MD, of University of Nebraska Medical Center

Dr. Bociek on the Clinical Uncertainty of MRD Negativity in CLL

R. Gregory Bociek, MD
April 6th 2021

R. Gregory Bociek, MD, discusses the clinical uncertainty of minimal residual disease negativity in chronic lymphocytic leukemia.

Read More

R. Gregory Bociek, MD

Dr. Bociek on the Role of MRD in CLL

R. Gregory Bociek, MD
March 11th 2021

R. Gregory Bociek, MD, discusses the role of minimal residual disease in patients with chronic lymphocytic leukemia.

Read More

R. Gregory Bociek, MD, of the University of Nebraska Medical Center

Dr. Bociek on Reserving Allo-SCT for Certain Patients with CLL

R. Gregory Bociek, MD
March 4th 2021

R. Gregory Bociek, MD, discusses the rationale to reserve allogeneic stem cell transplant for certain patients with chronic lymphocytic leukemia.

Read More

R. Gregory Bociek, MD, discusses outcomes for patients with chronic lymphocytic leukemia and COVID-19.

Dr. Bociek on Outcomes of Patients With CLL and COVID-19

R. Gregory Bociek, MD
March 2nd 2021

R. Gregory Bociek, MD, discusses outcomes for patients with chronic lymphocytic leukemia and COVID-19.

Read More

R. Gregory Bociek, MD, of the University of Nebraska Medical Center

Dr. Bociek on the Evolving Role of Prognostic Factors in CLL

R. Gregory Bociek, MD
February 24th 2021

R. Gregory Bociek, MD, discusses the evolving role of prognostic factors in chronic lymphocytic leukemia.

Read More

R. Gregory Bociek, MD, of University of Nebraska Medical Center

Dr. Bociek on the Evolving Role of Chemoimmunotherapy in CLL

R. Gregory Bociek, MD
February 22nd 2021

R. Gregory Bociek, MD, discusses the evolving role of chemoimmunotherapy in chronic lymphocytic leukemia.

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data